Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

The Cancer Genome Atlas Research Network*

ABSTRACT

BACKGROUND
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas.

METHODS
We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes.

RESULTS
Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma.

CONCLUSIONS
The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. ( Funded by the National Institutes of Health.)
DIFFUSE LOW-GRADE AND INTERMEDIATE-GRADE GLIOMAS (World Health Organization [WHO] grades II and III, hereafter called lower-grade gliomas) (see the Glossary) are infiltrative neoplasms that arise most often in the cerebral hemispheres of adults and include astrocytomas, oligodendrogliomas, and oligoastrocytomas.\(^1,2\) Because of their highly invasive nature, complete neurosurgical resection is impossible, and the presence of residual tumor results in recurrence and malignant progression, albeit at highly variable intervals. A subset of these gliomas will progress to glioblastoma (WHO grade IV gliomas) within months, whereas others remain stable for years. Similarly, survival ranges widely, from 1 to 15 years, and some lower-grade gliomas have impressive therapeutic sensitivity.\(^3-5\) Current treatment varies with the extent of resection, histologic class, grade, and the results of ancillary testing and includes clinical monitoring, chemotherapy, and radiation therapy, with salvage options available in the event of treatment failure.\(^6-8\)

Although the histopathological classification of lower-grade gliomas is time-honored, it suffers from high intraobserver and interobserver variability and does not adequately predict clinical outcomes.\(^9,10\) Consequently, clinicians increasingly rely on genetic classification to guide clinical decision making.\(^11-14\) Mutations in IDH1 and IDH2 (two very similar genes, hereafter referred to collectively as IDH) characterize the majority of lower-grade gliomas in adults and define a subtype that is associated with a favorable prognosis.\(^15-17\) Lower-grade gliomas with both an IDH mutation (i.e., a mutation in either IDH1 or IDH2) and deletion of chromosome arms 1p and 19q (1p/19q codeletion), which occurs most often in oligodendrogliomas, have better responses to radiochemotherapy and are associated with longer survival than diffuse gliomas without these alterations.\(^5,18\) TP53 and ATRX mutations are more frequent in astrocytomas and are also important markers of clinical behavior.\(^19\) To gain additional insight, we performed a comprehensive, integrative analysis of 293 lower-grade gliomas from adults, using multiple advanced molecular platforms. We performed an unsupervised analysis of integrated whole-genome molecular data to determine whether we could identify biologic classes of disease with clinically distinct behavior and to determine whether these classes were captured more accurately by molecular-marker status than by histologic class.

METHODS

PATIENTS

The tumor samples we analyzed were from 293 adults with previously untreated lower-grade gliomas (WHO grades II and III), including 100 astrocytomas, 77 oligoastrocytomas, and 116 oligodendrogliomas. Pediatric lower-grade gliomas were excluded; their molecular pathogenesis is distinct from that of lower-grade gliomas in adults.\(^20,21\) Diagnoses were established at the contributing institutions; neuropathologists in our consortium reviewed the diagnoses and ensured the quality of the diagnoses and of the tissue for molecular profiling (see Supplementary Appendix 1, available with the full text of this article at NEJM.org, for sample inclusion criteria). Patient characteristics are described in Table 1, and in Table S1 (Supplementary Appendix 2) and Table S2 in Supplementary Appendix 1. We obtained appropriate consent from relevant institutional review boards, which coordinated the consent process at each tissue-source site; written informed consent was obtained from all participants. The patients’ ages, tumor locations, clinical histories and outcomes, tumor histologic classifications, and tumor grades were typical of adults with a diagnosis of diffuse glioma.\(^1,2\)

ANALYTIC PLATFORMS

We performed exome sequencing (289 samples), DNA copy-number profiling (285), messenger RNA (mRNA) sequencing (277), microRNA sequencing (293), DNA methylation profiling (289), TERT promoter sequencing (287), and reverse-phase protein lysate array (RPPA) profiling (255).\(^22\) Complete data for all platforms were available for 254 samples. Whole-genome sequencing and low-pass whole-genome sequencing were performed on 21 and 52 samples, respectively. Molecular data were frozen on January 31, 2014, and clinical data were frozen on August 25, 2014. We also performed an unsupervised analysis (i.e., an analysis in which the categories are not known before computation) that integrated results from multiple platforms, including cluster of clusters (CoC) and OncoSign.\(^23\) In brief, CoC is a second-level clustering of class assignments derived from each individual molecular platform. OncoSign
classifies tumors on the basis of similarities in recurrent mutations and copy-number variations.

The complete data sets are provided in Table S1 (Supplementary Appendix 2). The primary sequence files are deposited in CGHub (https://cghub.ucsc.edu); all other data, including mutation annotation files, are deposited at the Cancer Genome Atlas Data Coordinating Center (http://cancergenome.nih.gov). Sample lists, data matrices, and supporting data are available at the Cancer Genome Atlas lower-grade glioma publication page (https://tcga-data.nci.nih.gov/docs/publications/lgg_2015).

STATISTICAL ANALYSIS

The statistical analysis included Fisher’s exact test for associations of categorical variables, one-way analysis of variance for association with continuous outcomes, Kaplan–Meier estimates of survival with log-rank tests among strata, and Cox proportional-hazards regression for multiple-predictor models of survival. A complete description of the methods is provided in Supplementary Appendix 1.

RESULTS

HISTOLOGIC AND MOLECULAR SUBTYPES

To compare the results from molecular platforms with both histologic classification and classification based on markers frequently used in clinical practice (IDH mutation and 1p/19q codeletion), we classified lower-grade gliomas into three categories: gliomas with an IDH mutation and 1p/19q codeletion, gliomas with an IDH mutation and no 1p/19q codeletion, and gliomas with wild-type IDH. We found a strong correlation between the presence of an IDH mutation and 1p/19q codeletion and the oligodendroglioma histologic class (69 of 84 samples) (Table 1,
Table 1. Clinical Characteristics of the Sample Set According to IDH Mutation and 1p/19q Codeletion Status.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (N = 278)†</th>
<th>IDH Mutation and 1p/19q Codeletion (N = 84)</th>
<th>IDH Mutation and No 1p/19q Codeletion (N = 139)</th>
<th>IDH Wild Type (N = 55)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histologic type‡ and grade‡ — no. (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oligodendroglioma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade II</td>
<td>65 (23)</td>
<td>38 (45)</td>
<td>21 (15)</td>
<td>6 (11)</td>
</tr>
<tr>
<td>Grade III</td>
<td>44 (16)</td>
<td>31 (37)</td>
<td>6 (4)</td>
<td>7 (13)</td>
</tr>
<tr>
<td>Oligoastrocytoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade II</td>
<td>41 (15)</td>
<td>9 (11)</td>
<td>30 (22)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Grade III</td>
<td>33 (12)</td>
<td>4 (5)</td>
<td>20 (14)</td>
<td>9 (16)</td>
</tr>
<tr>
<td>Astrocytoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade II</td>
<td>30 (11)</td>
<td>1 (1)</td>
<td>24 (17)</td>
<td>5 (9)</td>
</tr>
<tr>
<td>Grade III</td>
<td>65 (23)</td>
<td>1 (1)</td>
<td>38 (27)</td>
<td>26 (47)</td>
</tr>
<tr>
<td><strong>Age at diagnosis — yr‡</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>42.6±13.5</td>
<td>45.4±13.2</td>
<td>38.1±10.9</td>
<td>49.9±15.3</td>
</tr>
<tr>
<td>Range</td>
<td>14–75</td>
<td>17–75</td>
<td>14–70</td>
<td>21–74</td>
</tr>
<tr>
<td><strong>Male sex — no. (%)</strong></td>
<td>155 (56)</td>
<td>45 (54)</td>
<td>84 (60)</td>
<td>26 (47)</td>
</tr>
<tr>
<td><strong>White race — no./total no. (%)§</strong></td>
<td>261/274 (95)</td>
<td>79/81 (98)</td>
<td>131/138 (95)</td>
<td>51/55 (93)</td>
</tr>
<tr>
<td><strong>Year of diagnosis — no. (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before 2005</td>
<td>38 (14)</td>
<td>10 (12)</td>
<td>18 (13)</td>
<td>10 (18)</td>
</tr>
<tr>
<td>2010–2013</td>
<td>152 (55)</td>
<td>44 (52)</td>
<td>77 (55)</td>
<td>31 (56)</td>
</tr>
<tr>
<td><strong>Family history of cancer — no./total no. (%)¶</strong></td>
<td>108/190 (57)</td>
<td>30/58 (52)</td>
<td>64/98 (65)</td>
<td>13/34 (38)</td>
</tr>
<tr>
<td>None</td>
<td>11/190 (6)</td>
<td>2/58 (3)</td>
<td>7/98 (7)</td>
<td>2/34 (6)</td>
</tr>
<tr>
<td>Primary brain cancer</td>
<td>72/190 (38)</td>
<td>26/58 (45)</td>
<td>27/98 (28)</td>
<td>19/34 (56)</td>
</tr>
<tr>
<td><strong>Extent of resection — no./total no. (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Open biopsy</td>
<td>6/268 (2)</td>
<td>1/81 (1)</td>
<td>4/132 (3)</td>
<td>1/55 (2)</td>
</tr>
<tr>
<td>Subtotal resection</td>
<td>98/268 (37)</td>
<td>31/81 (38)</td>
<td>45/132 (34)</td>
<td>22/55 (40)</td>
</tr>
<tr>
<td>Gross total resection</td>
<td>164/268 (61)</td>
<td>49/81 (60)</td>
<td>83/132 (63)</td>
<td>32/55 (58)</td>
</tr>
<tr>
<td><strong>Tumor location — no. (%)‡</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frontal lobe</td>
<td>172 (62)</td>
<td>68 (81)</td>
<td>84 (60)</td>
<td>20 (36)</td>
</tr>
<tr>
<td>Parietal lobe</td>
<td>23 (8)</td>
<td>5 (6)</td>
<td>13 (9)</td>
<td>5 (9)</td>
</tr>
<tr>
<td>Temporal lobe</td>
<td>74 (27)</td>
<td>9 (11)</td>
<td>40 (29)</td>
<td>25 (45)</td>
</tr>
<tr>
<td>Other</td>
<td>9 (3)</td>
<td>2 (2)</td>
<td>2 (1)</td>
<td>5 (9)</td>
</tr>
<tr>
<td><strong>Laterality — no./total no. (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>133/276 (48)</td>
<td>37/84 (44)</td>
<td>69/137 (50)</td>
<td>27/55 (49)</td>
</tr>
<tr>
<td>Midline</td>
<td>5/276 (2)</td>
<td>2/84 (2)</td>
<td>2/137 (1)</td>
<td>1/55 (2)</td>
</tr>
<tr>
<td>Right</td>
<td>138/276 (50)</td>
<td>45/84 (54)</td>
<td>66/137 (48)</td>
<td>27/55 (49)</td>
</tr>
<tr>
<td><strong>White matter — no./total no. (%)</strong></td>
<td>74/144 (51)</td>
<td>26/48 (54)</td>
<td>37/72 (51)</td>
<td>11/24 (46)</td>
</tr>
<tr>
<td><strong>First presenting symptom — no./total no. (%)</strong></td>
<td>64/252 (25)</td>
<td>15/72 (21)</td>
<td>39/129 (30)</td>
<td>10/51 (20)</td>
</tr>
<tr>
<td>Headache</td>
<td>22/252 (9)</td>
<td>7/72 (10)</td>
<td>10/129 (8)</td>
<td>5/51 (10)</td>
</tr>
<tr>
<td>Mental status change</td>
<td>18/252 (7)</td>
<td>6/72 (8)</td>
<td>7/129 (5)</td>
<td>5/51 (10)</td>
</tr>
</tbody>
</table>
and Table S2 in Supplementary Appendix 1), a finding consistent with that in previous studies.\textsuperscript{24,25} Glioma samples with an \textit{IDH} mutation and no 1p/19q codeletion (139 samples, 50% of the cohort) represented a mixture of histologic classes but were enriched for astrocytomas and oligoastrocytomas. \textit{IDH} wild-type samples were mostly astrocytomas (31 of 55 samples) and grade III gliomas (42 of 55 samples), but this group included other histologic classes and grades. Overall, classification based on \textit{IDH}–1p/19q status correlated strongly with the oligodendroglioma histologic class but only modestly with astrocytoma and oligoastrocytoma.

**MULTIPLATFORM INTEGRATIVE ANALYSIS**

To determine whether advanced molecular profiling could subdivide lower-grade gliomas into discrete sets that are associated with biologic characteristics of disease, we performed unsupervised clustering of molecular data derived from four independent platforms and found well-defined clusters based on DNA methylation (five clusters) (Fig. S1 through S5 in Supplementary Appendix 1), gene expression (four clusters) (Fig. S6 and S7 in Supplementary Appendix 1 and Table S7), mRNA copy number (three clusters) (Fig. S8 in Supplementary Appendix 1), and microRNA expression (four clusters) (Fig. S9 and S10 in Supplementary Appendix 1 and Table S8) (Supplementary Appendix 7).

To integrate data and compare the resulting biologic classes with histologic classes and subtypes based on \textit{IDH}–1p/19q status, cluster group assignments from the four individual platforms (DNA methylation, mRNA, DNA copy number, and microRNA) were used for a second-level CoC analysis, resulting in three CoC clusters with distinctive biologic themes (Fig. 1). We found a strong correlation between CoC cluster assignment and molecular subtypes defined on the basis of \textit{IDH}–1p/19q codeletion status: most lower-grade gliomas with wild-type \textit{IDH} were in the CoC cluster that included mRNA cluster R2, microRNA cluster Mi3, DNA methylation cluster M4, and DNA copy number cluster C2. Another CoC cluster contained almost all gliomas with an \textit{IDH} mutation and 1p/19q codeletion and included primarily clusters R3, M2 and M3, and C3. The third CoC cluster was highly enriched for gliomas with an \textit{IDH} mutation and no 1p/19q codeletion and included clusters R1, M5, C1, and Mi1.

To determine the relative strength of clinical schemes for the classification of lower-grade gliomas in capturing the biologic subsets revealed by CoC analysis, we compared the correlation between \textit{IDH}–1p/19q subtype and CoC cluster assignment with the correlation between histologic class and CoC cluster assignment. Whereas 90% of samples with a specific \textit{IDH}–1p/19q designation mapped one-to-one with a predominant CoC cluster, only 63% of samples within a specific histologic class showed this predominant mapping. Moreover, the concordance between \textit{IDH}–1p/19q status and CoC cluster assignment was much greater than that between histologic subtype and CoC cluster assignment (adjusted Rand index, 0.79 vs. 0.19) (Table S2E in Supplementary Appendix 1), which indicates that \textit{IDH}–1p/19q...
The new england journal of medicine

status captures the biologic characteristics of lower-grade gliomas with greater fidelity than does histologic class.

**MUTATIONAL LANDSCAPE OF LOWER-GRADE GLIOMAS**

We generated a consensus mutation set with the use of three mutation-calling algorithms (see the Methods section in Supplementary Appendix 1); this yielded 9885 mutations detected in 289 samples (0.66 mutations per megabase in coding regions; median, 29 mutations per sample [range, 0 to 597]). Samples of lower-grade gliomas with wild-type IDH had more mutations (median, 45) than did samples with an IDH mutation and 1p/19q codeletion (median, 27; P<0.001) or those with an IDH mutation and no 1p/19q codeletion (median, 28; P<0.001) (Fig. S11, S12,

**Figure 1. Cluster of Clusters (CoC) Analysis.**

The results of multiplatform analyses point to biologic subtypes defined by IDH mutation and 1p/19q codeletion status. CoC analysis uses the cluster assignments derived from individual molecular platforms to stratify tumors, thereby integrating data from analysis of messenger RNA (mRNA) (designated by R on the y axis), microRNA (mi), DNA methylation (M), and copy number (C). For each sample, membership in a particular cluster is indicated by a yellow tick, and nonmembership is indicated by a blue tick. CoC analysis resulted in a strong three-class solution, and a comparison of tracks for CoC consensus cluster with tracks for histologic and molecular class shows a stronger correlation with molecular class.
and S13 in Supplementary Appendix 1). The prevalence of mutations in lower-grade gliomas, per individual sample, was lower than that in glioblastoma, higher than that in medulloblastoma, and intermediate in the spectrum of Cancer Genome Atlas–reported cancers (Fig. S11 in Appendix 1).22,28

We identified significant differences in DNA copy-number alterations and gene mutations among the three molecular subtypes (Fig. 2, 3, and 4, and Fig. S8 and S14 in Supplementary Appendix 1). Table S3 [Supplementary Appendix 3], and Table S4 in Supplementary Appendix 1). We found CIC mutations in 62% and FUBP1 mutations in 29% of lower-grade gliomas with an IDH mutation and 1p/19q codeletion, but we did not find these mutations in the other molecular subtypes. Among lower-grade gliomas with an IDH mutation and 1p/19q codeletion, we also observed mutations in the PI3 kinase pathway genes PIK3CA (20%) and PIK3R1 (9%) and in NOTCH1 (31%),29-31 as well as novel mutations in ZBTB20 (9%) and ARID1A (6%) (Fig. 2). In addition, among lower-grade gliomas with an IDH mutation and 1p/19q codeletion, we observed activating TERT promoter mutations, leading to elevated TERT expression; ATRX mutations were rare in these tumors, a finding consistent with the mutual exclusivity of ATRX and TERT mutations14,32 (Fig. 2 and 3). Focal amplification of 19p13.3 was noted (Fig. 3, and Fig. S14A in Supplementary Appendix 1), but few recurring whole-arm copy-number alterations other than 1p/19q codeletion were observed (Fig. S8B in Supplementary Appendix 1). Differences in the prevalence of mutations and the pattern of copy-number alterations between grade II and grade III lower-grade gliomas with an IDH mutation and 1p/19q codeletion were modest (Fig. 5A, and Fig. S21 in Supplementary Appendix 1).

Overall, the data suggest that lower-grade gliomas with an IDH mutation and 1p/19q codeletion are biologically discrete and arise from a sequence of IDH mutation, 1p/19q codeletion, and TERT activation; mutation of CIC and FUBP1; and activating alterations in the PI3 kinase pathway.29,31,32 NOTCH1 mutations in this subset of tumors probably inactivate the gene, because they occur at positions similar to those of NOTCH1 inactivating mutations in lung, head and neck, and cervical cancers and not at activation sites34 (Fig. S15 in Supplementary Appendix 1). The results of a PARADIGM-SHIFT35 analysis (Fig. S16 in Appendix 1), in which downstream targets are evaluated to assess pathway status, also suggested that NOTCH1 mutations result in inactivation of NOTCH1 protein function. Previous studies identified NOTCH1 mutations in oligodendroglioma and anaplastic astrocytoma; we noted them most often in lower-grade gliomas with an IDH mutation and 1p/19q codeletion, and they were rarely identified in lower-grade gliomas with an IDH mutation and no 1p/19q codeletion or in those with wild-type IDH (Fig. 2).29-31

Nearly all lower-grade gliomas with an IDH mutation and no 1p/19q codeletion (94%) harbored TP53 mutations, which suggests that this tumor class is defined by a loss of p53 function. Inactivating alterations of ATRX were frequent (86%) and included mutations (79%), deletions (3%), gene fusion (2%), or a combination of these events (2%).15 TERT promoter mutations were rare (4%), a finding consistent with the alternative mechanism of lengthening telomeres that is associated with ATRX mutations.32 We observed two novel significantly mutated genes in lower-grade gliomas with an IDH mutation and no 1p/19q codeletion: the SWI/SNF chromatin remodeler SMARCA4 (in 6% of these gliomas), which was previously implicated in glioma progression,36 and the translation initiation factor EIF1AX (in <1%), which was previously documented in uveal melanoma.37 Histologic grade III tumors in this subset had greater frequencies of chromosome 9p and 19q losses and of 10p gains (Fig. 5A), yet the mutational profiles did not differ substantially between grades (Fig. S21B in Supplementary Appendix 1). In the class of lower-grade gliomas with an IDH mutation, our multiplatform analysis suggests that there is a molecular progression that starts
Figure 2. Mutational Landscape of Somatic Alterations in Lower-Grade Glioma.

At the top of the figure, somatic mutation rates for each patient are stratified according to nonsynonymous (blue) and synonymous (green) mutations. In the middle portion of the figure, the clinical features associated with the patients are shown. At the bottom of the figure, genes that are significantly mutated (q value <0.1, determined with the use of the MutSig2CV algorithm) in lower-grade glioma are listed on the right. Samples from patients have been separated according to IDH mutation and 1p/19q codeletion status, with mutation types indicated in specific colors. NA denotes not applicable.
Figure 3. OncoSign Analysis.

Four main classes (OncoSign classes [OSCs]) can be identified by means of unbiased clustering of tumors on the basis of recurrent copy-number alterations, mutations, and gene fusions. White indicates that no information was available. OSCs are largely consistent with the molecular subtypes identified on the basis of IDH mutation and 1p/19q codeletion status, and they also correlate with the results of single-platform analysis. Combinations of selected genomic events, termed oncogenic signatures, characterize each OSC. A small group of samples showed none of the recurrent events used in this analysis and were therefore categorized as unclassified.

The New England Journal of Medicine
Downloaded from nejm.org at MIT LIBRARIES on January 27, 2016. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.
with initial IDH mutation and acquisition of the glioma CpG island methylation phenotype (G-CIMP, a specific pattern of widespread DNA hypermethylation) and is followed by either 1p/19q codeletion or TP53 mutation.19,31,38

**SIGNaling NETWORKS IN LOWER-GRADE GLIOMA**

To incorporate mutational landscapes into an unsupervised multiplatform classification, we performed OncoSign analysis23 with the use of 70 selected genetic events (mutation and copy number alteration) and identified four dominant subtypes (OSC1 to OSC4), which again largely recapitulated those defined by IDH–1p/19q status (adjusted Rand index, 0.83) (Fig. 3, and Table S2E in Supplementary Appendix 1). OSC1 was strongly correlated with lower-grade gliomas with an IDH mutation and no 1p/19q codeletion, and OSC4 contained exclusively lower-grade gliomas with wild-type IDH. The group with an IDH mutation and 1p/19q codeletion included both OSC2 and OSC3 lower-grade gliomas, which differed from one another with regard to mutations in CIC, FUBP1, and NOTCH1 yet were not substantially different in terms of tumor grade or pa-
Genomic Analysis of Lower-Grade Gliomas

Patient outcome. The concordance between IDH–1p/19q status and classes based on two different multiplatform approaches to genomic data integration (CoC and OncoSign) is striking and contrasts sharply with the much weaker correlation between histologic subtypes and unsupervised multiplatform classes (Table S2E in Supplementary Appendix 1). The finding that widely available markers (IDH and 1p/19q) can be used to classify lower-grade gliomas with results similar...
Mutations in seven genes were strongly associated with lower-grade gliomas that had wild-type IDH. Five of these genes have been reported to be mutated in glioblastoma: PTEN (in 23% of lower-grade gliomas with wild-type IDH), EGFR (in 27%), NF1 (in 20%), TP53 (in 14%), and PIK3CA (in 9%). We also found novel mutations in PTEN11, which encodes protein tyrosine phosphatase non-receptor 11 (in 7%), and in PLCG1, which encodes phospholipase C gamma 1 (in 5%) (Fig. 2). Similarly, copy-number alterations in tumors with wild-type IDH were distinct from lower-grade gliomas with mutated IDH and instead resembled glioblastomas with wild-type IDH (Fig. 5A). In particular, gains of chromosome 7 and deletions of chromosome 10 co-occurred in more than 50% of tumors of this subtype (chromosome 7 gains, 56%; chromosome 10 deletions, 63%), yet these alterations were absent in groups with mutated IDH. Recurring focal amplifications containing EGFR, MDM4, and CDK4 (in 38%, 13%, and 7% of tumors, respectively) and focal deletions targeting CDKN2A and RB1 (in 63% and 25%, respectively) were the most common acquired copy-number variants in lower-grade gliomas with wild-type IDH, findings similar to those for glioblastomas with wild-type IDH (Fig. 5B). Grade II gliomas with wild-type IDH were uncommon (13 cases), yet they differed from those that were grade III (Fig. S21C and S21D in Supplementary Appendix 1) in that they were strongly enriched within the discrete M1 DNA methylation cluster (Fig. 1, and Fig. S1A in Supplementary Appendix 1). Lower-grade gliomas in the M1 cluster that had wild-type IDH and were of grade II had a low prevalence of mutations and copy-number alterations, and they did not have TERT promoter mutations, which potentially indicates that they are distinct pathologic entities. TERT promoter mutations were present in 64% of all lower-grade gliomas with wild-type IDH; when M1 lower-grade gliomas were excluded from the analysis, TERT promoter mutations were present in 80% of those remaining, a prevalence similar to that in primary glioblastoma.22

**LOWER-GRADE GLIOMAS AND GLIOBLASTOMA WITH WILD-TYPE IDH**

**GENOMIC REARRANGEMENTS AND FUSION TRANSCRIPTS**

We investigated 20 samples with the use of high-coverage whole-genome sequencing, 50 samples with low-coverage whole-genome sequencing, and 311 samples with whole-exome sequencing, for structural chromosomal variants (e.g., translocations and inversions); we uncovered, with high confidence, 250 chromosomal rearrangements (Table S5 [Supplementary Appendix 4]). In addition, 19 samples had evidence of extra-chromosomal DNA structures known as double-minute chromosomes–breakpoint-enriched regions (DM-BERs) (Table S5 [Supplementary Appendix 4] and Fig. S17 in Supplementary Appendix 1). Of these, 15 occurred in lower-grade gliomas with wild-type IDH (27% of the samples) (Fig. 5A), a frequency similar to that seen with glioblastoma (23%).32,42 In an analysis of RNA sequencing data, we identified fusion transcripts in 265 lower-grade gliomas (Table S6 [Supplementary Appendix 5]), and correlation with structural genomic variants suggested chimeric transcription for 44% of the high-confidence chromosomal rearrangements, including two EGFR fusions (Fig. 5B), and for 58% of DM-BERs.33,44 Several genes (EGFR, FGFR3, NOTCH1, ATRX, and CDK4) were affected by fusions in multiple samples (Fig. S18A and S18B in Supplementary Appendix 1). Fusions that were predicted to activate EGFR and FGFR3 were restricted to lower-grade gliomas with wild-type IDH and were noted at frequencies similar to those in glioblastoma (7% and 3%, respectively) (Fig. S18A, S18B, and S19 in Supplementary Appendix 1).45,46 A novel chimeric FGFR3-ELAVL3 transcript involved the same breakpoint as previously reported for FGFR3-TACC3 fusions and was highly expressed, which suggests that it could have similar effects on FGFR3 function. Three samples had fusions between EGFR and intergenic or intronic chromosome 7 regions that are predicted to remove the EGFR autophosphorylation domain and are likely to be oncogenic (Fig. S18 in Supplementary Appendix 1).47 Fusions involving genes encoding receptor tyrosine kinases were predominantly a feature of lower-grade gliomas with wild-type IDH; only two lower-grade gliomas with an IDH mutation and no 1p/19q codeletion harbored such fusions.
PI3 kinase subunits, MAP kinases, NF1, sine kinases (EGFR fusions affecting genes that encode receptor tyrosine kinase pathways such as the EGFR pathway) in tumors with wild-type IDH, which provides additional support for the biologic similarity between lower-grade gliomas with wild-type IDH and glioblastoma (Fig. S20 in Supplementary Appendix 1). We observed overexpression of HER2, a potential therapeutic target, in tumors with wild-type IDH. Among lower-grade gliomas with mutated IDH, we observed higher expression of tyrosine protein kinase SYK, E-cadherin, and annexin 1 in the group without 1p/19q codeletion. Among lower-grade gliomas with an IDH mutation and 1p/19q codeletion, we noted higher levels of HER3 with a phosphorylated tyrosine residue at position 1289, a marker that potentially confers resistance to PI3 kinase inhibitors.

**From Signatures to Pathways**

To gain insights into signaling pathways, we performed an integrated analysis of mutations, focal copy-number alterations, structural variants, and fusions affecting genes that encode receptor tyrosine kinases (EGFR, PDGFRA, MET, and FGFR), PI3 kinase subunits, MAP kinases NF1 and BRAF, components of the p53 and RB1 pathways (MDM2, MDM4, MDM1, CDKN2A, and CDKN2B [hereafter referred to as CDKN2A/B], and CDKN2C), and ATRX. Alterations across these loci were remarkably similar in frequency between lower-grade gliomas with wild-type IDH and glioblastomas with wild-type IDH but not between these groups and other subtypes of lower-grade glioma (Fig. 5B, and Fig. S21E in Supplementary Appendix 1). A total of 43% of lower-grade gliomas with wild-type IDH and 53% of glioblastomas with wild-type IDH harbored EGFR alterations, with EGFR amplification being the most common aberration in both (Fig. S21 in Supplementary Appendix 1). Homozygous CDKN2A/B deletions occurred in 45% of lower-grade gliomas with wild-type IDH, which is similar to the frequency of these deletions in glioblastomas with wild-type IDH (55%). This contrasts with lower-grade gliomas with an IDH mutation and no 1p/19q codeletion, in which large single-copy deletions of chromosome 9p were common, yet CDKN2A/B was homozygously deleted in only 4% (Fig. S14B in Supplementary Appendix 1). Lower-grade gliomas with mutated IDH did not have cancer pathway aberrations similar to those of glioblastoma with wild-type IDH; instead, they had characteristic cancer pathway alterations in TP53 and ATRX (in the group with IDH mutation and no 1p/19q codeletion) and in TERT, NOTCH1, CIC, and FUBP1 (in the group with IDH mutation and 1p/19q codeletion) (Fig. S21E in Supplementary Appendix 1).

**Clinical Characteristics and Outcomes Associated with Molecular Subtypes**

Patients who had lower-grade gliomas with wild-type IDH were older than those who had lower-grade gliomas with mutated IDH and were more likely to have a family history of cancer (Table 1, and Table S2 in Supplementary Appendix 1). The anatomical locations of the tumors also differed; lower-grade gliomas with mutated IDH arose in frontal lobes more often than did those with wild-type IDH (P<0.05). Among the patients for whom clinical follow-up data were available, 77 of 250 (31%) had tumor recurrence, and 60 of 289 (21%) were deceased at the time of analysis. Patients who had lower-grade gliomas with wild-type IDH had substantially shorter overall survival than did those with lower-grade gliomas with mutated IDH (age-adjusted hazard ratio for death, 7.4; 95% confidence interval, 4.0 to 13.8). Their prognosis (median survival, 1.7 years) was intermediate between those of persons who had glioblastomas with wild-type IDH (median survival, 2.1 years) and those with an IDH mutation and no 1p/19q codeletion (Fig. 6B, and Table S2D in Supplementary Appendix 1). In comparison, persons who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had a median survival of 8.0 years, and those with an IDH mutation and no codeletion had a median survival of 6.3 years.

The molecular classification of lower-grade gliomas as having wild-type IDH, IDH mutation with no 1p/19q codeletion, or IDH mutation with 1p/19q codeletion stratified patient outcomes in multiple-predictor models after adjustment for age and extent of resection (Table S2B, S2C, and...
S2D in Supplementary Appendix 1). Grade, but not histologic class, remained a significant predictor of outcome in multivariable models with IDH–1p/19q status and provided additional prognostic value among the molecular subsets (Table S2 and Fig. S22 in Supplementary Appendix 1). Together, the results point to three robust tumor classes in lower-grade glioma, each with prototypical molecular alterations and distinctive clinical behavior (Fig. 4 and 6B).

**DISCUSSION**

We used a comprehensive, multiplatform genomics approach to delineate the biologic foundations of adult lower-grade glioma and conclude that genetic status was more reflective of disease subtypes than was histologic class. We base this conclusion on the results of an unsupervised analysis of genomewide molecular platforms, in which we identified three cohesive tumor classes that had distinct clinical behavior and were concordant with IDH, 1p/19q, and TP53 status to a greater extent than with histologic class. The three nonoverlapping molecular subtypes distilled from the six histologic and grade combinations lay the foundation for a reproducible and clinically relevant classification that incorporates molecular data into the pathological diagnosis, as is planned for the upcoming revision of the WHO classification of brain tumors.39,40

More specifically, we observed that two unsupervised, integrative genomewide analyses independently uncovered three primary lower-grade glioma disease classes that were best represented by IDH and 1p/19q status; that lower-grade gliomas with an IDH mutation had either 1p/19q codeletion or a TP53 mutation in a mutually exclusive fashion, which indicates a strict molecular dichotomy; and that the majority of lower-grade gliomas with wild-type IDH showed remarkable genomic and clinical similarity to primary (wild-type IDH) glioblastoma.

Numerous studies have shown that the histopathological classification of diffuse gliomas is prone to high interobserver variation, correlates inconsistently with genetic markers, and imperfectly predicts clinical outcomes.9,10 Like others, we found that lower-grade gliomas with an IDH mutation and 1p/19q codeletion were of the oligodendroglioma histologic class and were associated with favorable outcomes.3,4,14,18,24,49 However, lower-grade gliomas with wild-type IDH and those with mutated IDH and no 1p/19q codeletion had substantial representation from all three histologic classes (astrocytoma, oligodendrogli-
oma, and oligoastrocytoma), which highlights the discordance between histologic and genetic markers. In comparison, two unsupervised methods that integrated multiplatform molecular data (CoC and OncoSign) yielded strong correlations with IDH–1p/19q status (adjusted Rand index, 0.79 and 0.83, respectively), which showed that molecular classification captured biologic classes of disease more accurately than did histologic classification.

In addition, whereas oligodendrogliomas typically had 1p/19q codeletion and astrocytomas typically did not, oligoastrocytomas were distributed among the three molecular subtypes with no molecular feature distinguishing them. Thus, although previous WHO classifications have recognized lower-grade gliomas with mixed histologic features (oligoastrocytoma), our results indicate that lower-grade gliomas with IDH mutation have either 1p/19q codeletion or a TP53 mutation, with few gaps or overlaps, reflecting two distinct molecular mechanisms of oncogenesis, and they do not provide evidence for a biologic or genetic signature specific to oligoastrocytoma (Fig. 2, 3, and 4); this observation is consistent with those in previous studies.38,49-51 Molecular signatures of lower-grade glioma lend themselves to a practice-altering, biologically based classification system that should improve interobserver concordance. The implementation of this type of system also seems likely to reduce the diagnosis of “oligoastrocytoma” and the confusion related to its clinical management.

Another substantial finding was that tumors with wild-type IDH were molecularly and clinically distinct from subtypes with mutated IDH, with most showing a striking resemblance to primary glioblastoma on all analytic platforms. These findings suggest that lower-grade gliomas with wild-type IDH are likely to be immediate precursors of glioblastoma with wild-type IDH, since the median survival associated with this type of lower-grade glioma was only slightly longer than that associated with this type of glioblastoma (Fig. 6B). Alternatively, such tumors could represent glioblastomas that were incompletely sampled during surgery, in which case definitive histologic classification would be precluded. From a practical standpoint, sampling errors represent a challenge in surgical neuropathology, regardless of IDH status, class, or grade, because a histologic diagnosis is limited to findings under the microscope. Thus, molecular classification based on IDH–1p/19q status represents an improvement in diagnostic practice because it enables the identification of a clinically aggressive form of lower-grade glioma (with wild-type IDH) in the absence of morphologic criteria for glioblastoma.15,17

Our analysis of clinical outcomes showed that persons who had lower-grade gliomas with an IDH mutation and no 1p/19q codeletion had shorter overall survival than did those who had lower-grade gliomas with an IDH mutation with codeletion, yet both of these groups had substantially longer overall survival than did persons who had lower-grade gliomas with wild-type IDH.15 The stratification of clinical risk on the basis of IDH–1p/19q status is more robust than outcome predictions based on histologic class (Fig. 6, and Table S2 and Fig. S22 in Supplementary Appendix 1). Molecular classification can also provide quality control for histopathological diagnosis. For example, tumors in the small, discrete DNA methylation cluster M1 had a low frequency of mutations and copy-number alterations, yet tumors in this group occasionally contained BRAF alterations. Although they are not entirely specific, these alterations are more characteristic of grade I circumscribed tumors, such as pilocytic astrocytoma and ganglioglioma, and their presence would prompt consideration of alternative diagnoses.1,13 Although diffuse gliomas and circumscribed gliomas can occasionally overlap histologically, their associated prognosis and clinical management differ greatly. Molecular signatures offer the potential to resolve these diagnostically challenging cases.14 Further analysis of survival data in our cohort as it matures will be required to improve risk stratification with the use of molecular markers. In addition, ongoing acquisition and maturation of detailed data on treatment and outcomes will aid in the delineation of markers that are predictive of therapeutic response. In the meantime, however, the use of molecular classification can be integrated with other clinical, neuroimaging, and pathological data to devise a treatment strategy for individual patients.

It may transpire that distinct therapeutic strategies are required for effective disease control in molecular subtypes of lower-grade glioma. Molecular inclusion criteria and stratification in clinical-trial design will be necessary for a clear interpretation of outcomes from specific treatments. The prevalence of IDH mutations in lower-
grade glioma invites targeting of either the mutant enzymes themselves or their downstream metabolic and epigenomic consequences, such as G-CIMP.\textsuperscript{32} Mutations in \textit{ATRX}, \textit{CIC}, and \textit{FUBP1} have only recently been implicated in cancer pathogenesis, yet their specificity and prevalence in lower-grade glioma with an \textit{IDH} mutation support central roles in oncogenesis and argue for thorough characterization of associated signaling networks to facilitate therapeutic development. The genetic and clinical similarities between lower-grade glioma with wild-type \textit{IDH} and primary glioblastoma support the potential inclusion of this type of lower-grade glioma within the broad spectrum of glioblastoma-related clinical investigation and treatment protocols. Finally, our integrative analysis has shown that all subtypes of lower-grade glioma rely to some extent on core signaling networks that have previously been implicated in glioblastoma pathogenesis, many of which are targeted by agents that are being evaluated in clinical trials.

The views expressed in this article are those of the authors and do not reflect the official policy of the National Institutes of Health. Supported by grants (U24CA143883, U24CA143858, U24CA143840, U24CA143799, U24CA143835, U24CA143845, U24CA143882, U24CA143867, U24CA143866, U24CA143848, U24CA144025, U54HG003607, U54HG003079, U54HG003273, U24CA126543, U24CA126544, U24CA126546, U24CA126551, U24CA126554, U24CA126561, U24CA126563, U24CA143731, U24CA143843, and P30CA06672) from the National Institutes of Health.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank personnel at the genome sequencing centers and cancer genome characterization centers for data generation and analyses, members of the National Cancer Institute and National Human Genome Research Institute project teams for coordination of project activities, and personnel at the M.D. Anderson Functional Proteomics for RPPA data and analysis.

APPENDIX

The authors’ full names and academic degrees are as follows: Daniel J. Brat, M.D., Ph.D., Noel G. Verhaak, Ph.D., Kenneth D. Altshuler, M.D., Ph.D., W.K. Alfred Yung, M.D., Sofie R. Salama, Ph.D., Lee A.D. Cooper, Ph.D., Esther Rheinbay, Ph.D., C. Ryan Miller, M.D., Ph.D., Mark Vitucci, Ph.D., Olene Morozova, Ph.D., A. Gordon Robertson, Ph.D., Houtan Noushmehr, M.D., Peter W. Laird, Ph.D., Andrew D. Cherniack, Ph.D., Rehan Akbani, Ph.D., Jason T. Huse, M.D., Ph.D., Giovanni Ciriello, Ph.D., Laila M. Poisson, Ph.D., Jill S. Barnholtz-Sloan, Ph.D., Mitchel S. Berger, M.D., Cameron Brennan, M.D., Rivka R. Cohen, M.D., Howard Colman, M.D., Ph.D., Adam E. Flanders, M.D., Caterina Giannini, M.D., Ph.D., Mia Grippo, Ph.D., Antonio Lavarone, M.D., Rajan Jain, M.D., Isaac Joseph, B.S., Jaegi Kim, Ph.D., Katayoon Kassam, B.S., Tom Mikkelson, M.D., Bradley A. Murray, B.S., Brian Patrick O’Neill, M.D., Lior Pachter, Ph.D., Donald W. Parsons, M.D., Ph.D., Carrie Sougnez, B.S., Erik P. Sulman, M.D., Ph.D., Scott R. Vandenberg, M.D., Ph.B., Erwin G. Van Meir, Ph.D., Andreas von Deimling, M.D., Hailei Zhang, Ph.D., Daniel Crain, M.B.A., Kevin Lau, B.S., David Malleroy, M.D., M.B.A., J.D., Scott Morris, P.S.M., Ph.D., Joseph Paulauskis, Ph.D., Robert Penny, M.D., Ph.D., Troy Shelly, M.P.P., Mark Sherman, Ph.D., Peggy Yen, B.S., Aaron Black, B.S., Jay Bowen, M.S., Katie Dickostanoz, B.S., Julie Gastier-Foster, Ph.D., Kristen M. Lerasa, M.S., Tara M. Lichtenberg, B.A., Christopher R. Pierson, M.D., Ph.D., Nilsa C. Ramirez, M.D., Cynthia Taylor, B.S., Stephanie Weaver, Lisa Wise, Eirk Zmuda, Ph.D., Tanja Davidsen, Ph.D., John A. Demchok, M.S., Greg Eley, Ph.D., Martin L. Ferguson, Ph.D., Carolyn M. Hubble, Pet Dr., Kenna R. Mills, Shaw, Ph.D., Bradley A. Ozencberger, Ph.D., Margri Sheth, B.S., Heid J. Sofia, Ph.D., Roy Tarnuzner, Ph.D., Zhining Wang, Ph.D., Liming Yang, Ph.D., Jean Claude Zenklusen, Ph.D., Brenda Ayala, B.S., Julien Baboud, B.S., Sudha Chudamani, M.Phil., Mark A. Jensen, Ph.D., Jian Liu, Ph.D., Todd Pil, Ph.D., Rohini Raman, B.S., Yinhua Wu, Ph.D., Ye Wu, Ph.D., Adrian Ally, B.S., J. Todd Auman, Ph.D., Minerva Balasundaram, B.S., Saiandand Balu, M.S., Stephen B. Baylin, M.D., Rameen Beroukhim, M.D., Ph.D., Moiz S. Boowalla, M.S., Reanne Bowley, M.S., Christopher A. Bristow, Ph.D., Denise Brooks, Ph.D., Varon Butterfield, B.S., Rebecca Carlsen, M.D., Scott Carter, Ph.D., Lynda Chin, M.D., Andy Chu, B.S., Eric Chuh, B.S., Kristian Cibulskis, B.S., Amanda Clarke, Simon G. Coetzee, Noreen Dhallia, B.S., Tim Fennel, M.S., Sheila Fisher, M.B.A., Stacey Gabriel, Ph.D., Gad Getz, Ph.D., Richard Gibbs, Ph.D., Ranabir Guin, B.S., Angela Hadjianaparviant, Ph.D., D. Neil Hayes, M.P.H., M.P.H., Toshinori Hinoue, Ph.D., Katherine Hoadley, Ph.D., Robert A. Holt, Ph.D., Alan P. Hoyle, B.S., Stuart R. Jefferies, Ph.D., Steven Jones, Ph.D., Corbin D. Jones, Ph.D., Raju Kucherlapati, Ph.D., Phillip H. Lai, B.S., Eric Lander, Ph.D., Semin Lee, Ph.D., Lee Lichtenstein, M.S., Yussanne Ma, Ph.D., Denisa T. Mfalafina, M.S., Harshad S. Mahadeshwar, M.S., Marco A. Marra, Ph.D., Michael Mayo, B.S., Shaoowo Meng, Ph.D., Matthew L. Meyermonson, M.D., Ph.D., Piotr A. Mieczkowski, Ph.D., Richard A. Moore, Ph.D., Lisele E. Mose, B.S., Andrew J. Mungall, Ph.D., Angeliki Pantazi, M.D., Ph.D., Michael Parfenov, M.D., Ph.D., Peter J. Park, Ph.D., Joel S. Parker, Ph.D., Charles M. Perou, Ph.D., Alexei Protanides, Ph.D., Xiaojia Ren, M.A., M.S., Jeffrey Roach, Ph.D., Thais S. Sabedot, B.S., Jacqueline Schein, M.S., Steven E. Schumacher, M.S., Jonathan G. Seidman, Ph.D., Sahil Seth, M.S., Hui Shen, Ph.D., Janae V. Simons, B.S., Payal Sipahimalani, M.S., Matthew G. Soloway, Ph.D., Xingxi Song, Ph.D., Huadong Song, Sun, M.S., Barbara Tabak, Ph.D., Angela Tama, B.S., Donghui Tan, M.S., Jiabin Tang, Ph.D., Nina Thiessen, M.S., Timothy Triche, Jr., Ph.D., David J. Van Den Berg, Ph.D., Umadevi Veluvelu, M.Phil., Scot Waring, Ph.D., Daniel J. Weisenberger, Ph.D., Matthew D. Wilkerson, Ph.D., Tina Wong, B.S., Junyuan Wu, M.S., Liu Xi, M.S., Andrew W. Xu, Ph.D., Lixing Yang, Ph.D., Travis I. Zack, B.A., Jianhua Zhang, Ph.D., Arman Aksoy, Ph.D., Harinda Arachchi, B.S., M.B.A., Chris Benz, M.D., Brady Bernard, Ph.D., Daniel Carlin, Ph.D., Juho Cho, Ph.D., Daniel DiCarlo, M.S., Scott Frazer, Gregory N. Fuller, M.D., Ph.D., Jiankang Gao, Ph.D., Nils Gehlenborg, Ph.D., David Haussler, Ph.D., David I. Heiman, B.S., Lisa Iype, Ph.D., Anders Jacobsen, Ph.D., Zhenlin Ju, Ph.D., Sol Katzman, Ph.D., Hoon Kim, Ph.D., Theo Kleinjens, Ph.D., Richard Bailey Kreisberg, M.S., Michael S. Lawrance, Ph.D., William Lee, Ph.D., Kalle Leinonen, M.S., Pei Lin, M.D., M.S., Shiyan Ling, Ph.D., Wenbin Liu, M.S., Yequn Liu, Ph.D., Yuchen Li, Ph.D., Yiling Lu, M.D., Gordon Mills, M.D., Ph.D., Sam Ng, B.S., Michael S. Noble, M.S., Evan Paull, B.S., Arvind Rao, Ph.D., Sheila Reynolds, Ph.D., Gordon Saksena, M.Eng., Zack Samborn, Ph.D., Chris Sander, Ph.D., Nikolaus Schulz, Ph.D., Yasin Senabagouli, Ph.D., Ronghai Shen, Ph.D., Ilya Shumulevich, Ph.D., Rineen Sinha, Ph.D., Josh Stuart, Ph.D., S. Onur Sumer, M.S., Yichao Sun, M.S., Natalie Tasman, B.A., Barry S. Taylor, Ph.D., Doug Voet, M.S., Nils Weinhold, Ph.D., John N. Weinstein, M.D., Ph.D., Da
Comparison of a strategy favoring early clinical trials on glioma: a clinician’s perspective.

References


Genomic Analysis of Lower-Grade Gliomas


Copyright © 2015 Massachusetts Medical Society.